Pharmacological and biological therapeutic strategies for osteogenesis imperfecta
- 3 November 2016
- journal article
- review article
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 172 (4) , 367-383
Abstract
Osteogenesis imperfecta (OI) is a connective tissue disorder characterized by bone fragility, low bone mass, and bone deformities. The majority of cases are caused by autosomal dominant pathogenic variants in the COL1A1 and COL1A2 genes that encode type I collagen, the major component of the bone matrix. The remaining cases are caused by autosomal recessively or dominantly inherited mutations in genes that are involved in the post‐translational modification of type I collagen, act as type I collagen chaperones, or are members of the signaling pathways that regulate bone homeostasis. The main goals of treatment in OI are to decrease fracture incidence, relieve bone pain, and promote mobility and growth. This requires a multi‐disciplinary approach, utilizing pharmacological interventions, physical therapy, orthopedic surgery, and monitoring nutrition with appropriate calcium and vitamin D supplementation. Bisphosphonate therapy, which has become the mainstay of treatment in OI, has proven beneficial in increasing bone mass, and to some extent reducing fracture risk. However, the response to treatment is not as robust as is seen in osteoporosis, and it seems less effective in certain types of OI, and in adult OI patients as compared to most pediatric cases. New pharmacological treatments are currently being developed, including anti‐resorptive agents, anabolic treatment, and gene‐ and cell‐therapy approaches. These therapies are under different stages of investigation from the bench‐side, to pre‐clinical and clinical trials. In this review, we will summarize the recent findings regarding the pharmacological and biological strategies for the treatment of patients with OI.Keywords
Funding Information
- NIH grants (P01 HD70394, AI036211, CA125123, RR024574)
- Eunice Kennedy Shriver National Institute of Child Health & Human Development (HD024064)
- Rolanette and Berdon Lawrence Bone Disease Program of Texas
- BCM Center for Skeletal Medicine and Biology
- Genzyme-ACMG Foundation Medical Genetics Training Award in Clinical Biochemical Genetics
- Michael Geisman-Osteogenesis Imperfecta Foundation (OIF) Fellowship Award
This publication has 176 references indexed in Scilit:
- WNT1 Mutations in Early-Onset Osteoporosis and Osteogenesis ImperfectaNew England Journal of Medicine, 2013
- Next-generation sequencing for disorders of low and high bone mineral densityOsteoporosis International, 2013
- Phenotypic Variability of Osteogenesis Imperfecta Type V Caused by an IFITM 5 MutationJournal of Bone and Mineral Research, 2013
- Endoplasmic reticulum stress or mutation of an EF-hand Ca2+-binding domain directs the FKBP65 rotamase to an ERAD-based proteolysisCell Stress and Chaperones, 2011
- Mutations in SERPINF1 cause osteogenesis imperfecta type VIJournal of Bone and Mineral Research, 2011
- Mutations in FKBP10 cause recessive osteogenesis imperfecta and bruck syndromeJournal of Bone and Mineral Research, 2010
- Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal-Recessive Osteogenesis ImperfectaThe American Journal of Human Genetics, 2010
- Homozygosity for a Missense Mutation in SERPINH1, which Encodes the Collagen Chaperone Protein HSP47, Results in Severe Recessive Osteogenesis ImperfectaThe American Journal of Human Genetics, 2010
- PPIB Mutations Cause Severe Osteogenesis ImperfectaThe American Journal of Human Genetics, 2009
- CRTAPandLEPRE1mutations in recessive osteogenesis imperfectaHuman Mutation, 2008